Ensitrelvir - Shionogi
Alternative Names: Ensitrelvir fumarate - Shionogi; Ensitrelvir fumaric acid - Shionogi; S-217622; SARS-CoV2 3C-like protease inhibitor - Shionogi; XocovaLatest Information Update: 05 Aug 2026
At a glance
- Originator Hokkaido University; Shionogi
- Developer Juniper Therapeutics; Shionogi
- Class Amines; Antivirals; Chlorine compounds; Fluorobenzenes; Indazoles; Ketones; Small molecules; Triazines; Triazoles
- Mechanism of Action Coronavirus 3C protease inhibitors
-
Orphan Drug Status
No
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
Highest Development Phases
- Marketed COVID 2019 infections
- Clinical Phase Unknown Post acute COVID 19 syndrome
Most Recent Events
- 28 Jul 2026 Launched for COVID-2019 infections (In adolescents, In adults, Prevention, In the elderly) in USA (PO)
- 19 Jun 2026 Registered for COVID-2019 infections (In children) in Japan (PO)
- 01 Jun 2026 Registered for COVID-2019 infections (In the elderly, In adolescents, Prevention, In adults) in USA (PO)